MASH Diagnostics Market - 2026-2035

June 2026 | 42 pages | ID: M94505329AB4EN
DataM Intelligence

Abstracts

MASH Diagnostics Market reached US$ 1.41 Billion in 2025 and is expected to reach US$ 7.72 billion by 2035, growing with a CAGR of 23.94% during the forecast period 2026-2035.

The MASH Diagnostics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A MASH Diagnostics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Diagnostic Workflow Stage

• Initial Screening Methods*
• Liver Function Tests
• ALT Testing
• AST Testing
• Platelet Count
• Ultrasound Screening
• Primary Care Risk Screening
• Diabetes Screening Based Liver Assessment
• Obesity Risk Based Screening
• Metabolic Syndrome Screening
• MASH Confirmation Methods
• Liver Biopsy
• MRI PDFF
• Magnetic Resonance Elastography
• FibroScan Confirmation
• Histopathology Confirmation
• Biomarker Based Confirmation
• Combined Imaging and Biomarker Confirmation
• Fibrosis Staging Methods
• FIB 4 Score
• NAFLD Fibrosis Score
• Enhanced Liver Fibrosis Test
• FibroScan
• APRI Score
• Liver Biopsy Staging
• Histological Fibrosis Grading
• Others
• Treatment Monitoring Methods
• ALT Monitoring
• AST Monitoring
• FibroScan Follow Up
• MRI PDFF Follow Up
• Biomarker Monitoring
• Repeat Liver Function Testing
• Disease Regression Tracking
• Disease Progression Surveillance Methods
• Fibrosis Monitoring
• Cirrhosis Risk Tracking
• Repeat Imaging Assessment
• Liver Function Monitoring
• Hepatology Follow Up
• Longitudinal Biomarker Tracking
• Emerging Diagnostic Technologies
• AI Based Risk Scoring
• AI Imaging Interpretation
• Multiomics Diagnostics
• Genomic Risk Profiling
• RNA Biomarkers
• Digital Pathology
• Predictive Analytics Platforms
• Companion Diagnostics

By Diagnostic Method

• Imaging Diagnostics*
• Ultrasound
• FibroScan
• MRI PDFF
• Magnetic Resonance Elastography
• CT Imaging
• Contrast Enhanced Imaging
• Blood Based Diagnostics
• Liver Enzyme Tests
• ALT and AST
• Enhanced Liver Fibrosis Test
• FIB 4 Index
• NAFLD Fibrosis Score
• Cytokeratin 18 Biomarkers
• Inflammatory Biomarkers
• Lipid Profile Markers
• Others
• Histopathology Diagnostics
• Liver Biopsy
• Histological Grading
• Fibrosis Scoring
• Tissue Based Biomarker Analysis
• Molecular Diagnostics
• RNA Biomarkers
• DNA Biomarkers
• Genomic Panels
• Multiomics Diagnostics
• Precision Biomarker Panels
• AI Enabled Diagnostics
• AI Imaging Algorithms
• Automated Fibrosis Scoring
• Predictive Risk Models
• Digital Liver Pathology

By Diagnostic Purpose

• Screening Diagnostics*
• Disease Confirmation Diagnostics
• Fibrosis Staging Diagnostics
• Therapy Eligibility Diagnostics
• Companion Diagnostics
• Treatment Monitoring Diagnostics
• Disease Surveillance Diagnostics
• Progression Tracking Diagnostics

By Disease Severity

• MASLD*
• Early MASH
• Mild Fibrosis
• Moderate Fibrosis
• Advanced Fibrosis
• Severe Fibrosis
• Cirrhosis Stage
• High Risk Progression Population

By End-User

• Hospitals*
• Hepatology Clinics
• Gastroenterology Clinics
• Diagnostic Laboratories
• Imaging Centers
• Specialty Liver Centers
• Academic Research Centers
• Ambulatory Diagnostic Centers

Regional Analysis for MASH Diagnostics Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global MASH Diagnostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Data
  1.1.1. Secondary Data
  1.1.2. Primary Data
  1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
  1.2.1. Bottom-Up Approach
  1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations

2. DEFINITION AND OVERVIEW

2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period

3. EXECUTIVE SUMMARY

3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Shift From Biopsy Toward Non-invasive Fibrosis Assessment Is Accelerating Adoption
    4.1.1.2. Metabolic-risk Screening Is Shifting MASH Diagnosis from Hepatology Clinics to Primary Care and Diabetes Care
    4.1.1.3. Fibrosis Staging Is Becoming the Key Decision Layer in MASH Diagnostic Workflows
  4.1.2. Restraints
    4.1.2.1. Advanced imaging and specialty tests remain unevenly accessible across regions
    4.1.2.2. Indeterminate fibrosis scores are creating diagnostic uncertainty and referral burden
  4.1.3. Impact Analysis - Drivers and Restraints
  4.1.4. Opportunity
    4.1.4.1. AI enabled imaging and pathology can improve diagnostic confidence and workflow speed
    4.1.4.2. Second-line blood biomarker adoption can unlock fibrosis assessment where imaging capacity is limited
  4.1.5. Trends
    4.1.5.1. Metabolic Disease Surge and GLP-1 Adoption Are Expanding the MASH Diagnostic Funnel
    4.1.5.2. Therapy Approvals Are Repositioning MASH Diagnostics as a Treatment Access Gatekeeper
  4.1.6. Challenges

5. INDUSTRY ANALYSIS

5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors
  5.3.1. Rising awareness of metabolic health, obesity-linked liver complications and diabetes-associated liver risk is increasing demand for early MASH screening among high-risk patient groups.
  5.3.2. Growing patient preference for non-invasive diagnostics is supporting wider adoption of imaging, blood-based biomarkers and fibrosis scoring tools as alternatives to repeated liver biopsy.
  5.3.3. Increasing physician focus on early liver disease detection is strengthening diagnostic referrals from endocrinology, gastroenterology, hepatology and primary care settings.
5.4. Economic Factors
  5.4.1. Rising healthcare costs associated with advanced fibrosis, cirrhosis, liver failure and transplant care are driving investment in earlier MASH diagnosis and disease progression monitoring.
  5.4.2. Increasing payer and hospital focus on risk stratification is creating demand for cost-effective diagnostic workflows that identify therapy-eligible patients before severe liver damage develops.
  5.4.3. Growing pharmaceutical investment in MASH drug development is expanding the need for diagnostic tools that support patient screening, fibrosis staging, trial enrollment and treatment response monitoring.
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion

6. BY DIAGNOSTIC WORKFLOW STAGE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Workflow Stage
  6.1.2. Market Attractiveness Index, By Diagnostic Workflow Stage
6.2. Initial Screening Methods*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  6.2.3. Liver Function Tests
    6.2.3.1. ALT Testing
    6.2.3.2. AST Testing
  6.2.4. Platelet Count
  6.2.5. Ultrasound Screening
  6.2.6. Primary Care Risk Screening
  6.2.7. Diabetes Screening Based Liver Assessment
  6.2.8. Obesity Risk Based Screening
  6.2.9. Metabolic Syndrome Screening
6.3. MASH Confirmation Methods
  6.3.1. Liver Biopsy
  6.3.2. MRI PDFF
  6.3.3. Magnetic Resonance Elastography
  6.3.4. FibroScan Confirmation
  6.3.5. Histopathology Confirmation
  6.3.6. Biomarker Based Confirmation
  6.3.7. Combined Imaging and Biomarker Confirmation
6.4. Fibrosis Staging Methods
  6.4.1. FIB 4 Score
  6.4.2. NAFLD Fibrosis Score
  6.4.3. Enhanced Liver Fibrosis Test
  6.4.4. FibroScan
  6.4.5. Magnetic Resonance Elastography
  6.4.6. APRI Score
  6.4.7. Liver Biopsy Staging
  6.4.8. Histological Fibrosis Grading
  6.4.9. Others
6.5. Treatment Monitoring Methods
  6.5.1. ALT Monitoring
  6.5.2. AST Monitoring
  6.5.3. FibroScan Follow Up
  6.5.4. MRI PDFF Follow Up
  6.5.5. Biomarker Monitoring
  6.5.6. Repeat Liver Function Testing
  6.5.7. Disease Regression Tracking
6.6. Disease Progression Surveillance Methods
  6.6.1. Fibrosis Monitoring
  6.6.2. Cirrhosis Risk Tracking
  6.6.3. Repeat Imaging Assessment
  6.6.4. Liver Function Monitoring
  6.6.5. Hepatology Follow Up
  6.6.6. Longitudinal Biomarker Tracking
6.7. Emerging Diagnostic Technologies
  6.7.1. AI Based Risk Scoring
  6.7.2. AI Imaging Interpretation
  6.7.3. Multiomics Diagnostics
  6.7.4. Genomic Risk Profiling
  6.7.5. RNA Biomarkers
  6.7.6. Digital Pathology
  6.7.7. Predictive Analytics Platforms
  6.7.8. Companion Diagnostics
  6.7.9. Others

7. BY DIAGNOSTIC METHOD

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
  7.1.2. Market Attractiveness Index, By Diagnostic Method
7.2. Imaging Diagnostics*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  7.2.3. Ultrasound
  7.2.4. FibroScan
  7.2.5. MRI PDFF
  7.2.6. Magnetic Resonance Elastography
  7.2.7. CT Imaging
  7.2.8. Contrast Enhanced Imaging
7.3. Blood Based Diagnostics
  7.3.1. Liver Enzyme Tests
    7.3.1.1. ALT and AST
  7.3.2. Enhanced Liver Fibrosis Test
  7.3.3. FIB 4 Index
  7.3.4. NAFLD Fibrosis Score
  7.3.5. Cytokeratin 18 Biomarkers
  7.3.6. Inflammatory Biomarkers
  7.3.7. Lipid Profile Markers
  7.3.8. Others
7.4. Histopathology Diagnostics
  7.4.1. Liver Biopsy
  7.4.2. Histological Grading
  7.4.3. Fibrosis Scoring
  7.4.4. Tissue Based Biomarker Analysis
7.5. Molecular Diagnostics
  7.5.1. RNA Biomarkers
  7.5.2. DNA Biomarkers
  7.5.3. Genomic Panels
  7.5.4. Multiomics Diagnostics
  7.5.5. Precision Biomarker Panels
  7.5.6. Others
7.6. AI Enabled Diagnostics
  7.6.1. AI Imaging Algorithms
  7.6.2. Automated Fibrosis Scoring
  7.6.3. Predictive Risk Models
  7.6.4. Digital Liver Pathology

8. BY DIAGNOSTIC PURPOSE

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Purpose
  8.1.2. Market Attractiveness Index, By Diagnostic Purpose
8.2. Screening Diagnostics*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Disease Confirmation Diagnostics
8.4. Fibrosis Staging Diagnostics
8.5. Therapy Eligibility Diagnostics
8.6. Companion Diagnostics
8.7. Treatment Monitoring Diagnostics
8.8. Disease Surveillance Diagnostics
8.9. Progression Tracking Diagnostics

9. BY DISEASE SEVERITY

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Severity
  9.1.2. Market Attractiveness Index, By Disease Severity
9.2. MASLD*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Early MASH
9.4. Mild Fibrosis
9.5. Moderate Fibrosis
9.6. Advanced Fibrosis
9.7. Severe Fibrosis
9.8. Cirrhosis Stage
9.9. High Risk Progression Population

10. BY END-USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hepatology Clinics
10.4. Gastroenterology Clinics
10.5. Diagnostic Laboratories
10.6. Imaging Centers
10.7. Specialty Liver Centers
10.8. Academic Research Centers
10.9. Ambulatory Diagnostic Centers

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America*
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User
  11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.8.1. U.S.
    11.2.8.2. Canada
    11.2.8.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User
  11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.8.1. Germany
    11.3.8.2. UK
    11.3.8.3. France
    11.3.8.4. Russia
    11.3.8.5. Spain
    11.3.8.6. Italy
    11.3.8.7. Poland
    11.3.8.8. Rest of Europe
11.4. Latin America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User
  11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.8.1. Brazil
    11.4.8.2. Argentina
    11.4.8.3. Rest of Latin America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User
  11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.8.1. China
    11.5.8.2. India
    11.5.8.3. Japan
    11.5.8.4. Australia
    11.5.8.5. South Korea
    11.5.8.6. Indonesia
    11.5.8.7. Malaysia
    11.5.8.8. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Workflow
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Method
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis, By Diagnostic Purpose
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis, By Disease Severity
  11.6.7. Market Size Analysis and Y-o-Y Growth Analysis, By End-User
  11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.6.8.1. UAE
    11.6.8.2. Saudi Arabia
    11.6.8.3. South Africa
    11.6.8.4. Israel
    11.6.8.5. Turkiye
    11.6.8.6. Rest of Middle East and Africa

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Share Analysis - Global
12.3. Market Share Analysis - North America
12.4. Market Share Analysis - Europe
12.5. Market Share Analysis - Asia-Pacific
12.6. Mergers and Acquisitions Analysis
12.7. Partner Identification Analysis
12.8. Investment & Funding Landscape
12.9. Strategic Alliances & Innovation Pipeline

13. COMPANY PROFILES

13.1. Echosens*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Revenue Analysis
  13.1.4. Pricing Analysis
  13.1.5. SWOT Analysis
  13.1.6. Recent Developments
    13.1.6.1. Major Deals
    13.1.6.2. M&A
    13.1.6.3. Collaboration
    13.1.6.4. Acquisition
    13.1.6.5. Joint Ventures
    13.1.6.6. Innovations
  13.1.7. Recent News
    13.1.7.1. Events
    13.1.7.2. Conferences
    13.1.7.3. Symposiums
    13.1.7.4. Webinars
13.2. Siemens Healthineers AG
13.3. Perspectum Limited
13.4. Nordic Bioscience
13.5. BioPredictive
13.6. Rubi? Metabolomics
13.7. PathAI, Inc.
13.8. Histoindex Pte Ltd.
13.9. F. Hoffmann-La Roche Ltd.
13.10. GE HealthCare
13.11. Koninklijke Philips N.V. LIST NOT EXHAUSTIVE

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us